|
Flavay's™
strong antioxidant power is patented—as a scavenger of
the free radicals
that play a major role in the initiation, duration and
breakdown
of inflammation and the degradation of collagen.
Flavay™ has been licensed and
sold in France for reducing inflammation and edema (swelling)
since 1950 and is now available
in the United States as a dietary supplement. Research shows
several ways that Flavay™ can stimulate the immune response to
help normalize the balance of chemicals in the body that control
pain and inflammation.
Naturally
Inhibit Inflammation
Flavay™
can selectively bind to the connective tissue of joints,
preventing inflammation and lessening pain.
|
Inflammation is caused by the
overproduction of free radicals in a specific area of the body. We
now know that antioxidants work together to defeat free radicals
and inhibit the biological pathway that triggers inflammation, and
Flavay™ is particularly effective as an
anti-inflammatory.
Research demonstrates that Flavay™
can selectively bind to the connective tissue of joints,
preventing inflammation and lessening pain. In fact, one of the
very first benefits observed and studied Dr. Jack Masquelier, in
as early as 1947, was the anti-inflammatory effect of Flavay™.
Research demonstrates that Flavay™
inhibits the release and synthesis of histamine (which produces
accelerated blood flow, dilates capillaries and increases their
permeability, thereby leaking plasma into surrounding tissue), a
key factor in the promotion of inflammation.
Studies demonstrate that the
anti-histamine action of Flavay™ is obtained through inhibiting
the activity of the enzyme histidine decarboxylase. Dr.
Masquelier’s research has been confirmed by German studies which
show that Flavay™ may lower the production of histamine with as
much as 86% inhibition of histidine decarboxylase.
Flavay™ also neutralizes free
radicals that promote swelling and cause inflammation. A free
radical called superoxide is involved in the inflammation of
arthritis. Flavay™ readily quenches the superoxide free
radicals.
Edema
(Swelling)
Edema is an uncomfortable
condition and can be both painful and dangerous. Swollen and
painful legs and ankles, puffiness of the eyes and an overall
bloated look and feel are examples of edema. It involves the
leakage of blood serum into surrounding tissues and Flavay™ has
shown that it can reduce this leakage by strengthening capillary
walls.
All
of those taking Flavay™ for edema (swelling) had
relief from at least some of the symptoms.
|
Italian scientists from the
University of Florence studied the effect of Flavay™ on venous
congestion (edema) in the legs. The study involved 40 subjects
consisting of 13 men and 27 women between the ages of 34 and 74.
The subjects were randomly divided into two groups. One group
received a placebo and the other group received 300 mg of Flavay™
daily for 60 days.
All of those taking the Flavay™
had relief from at least some of the symptoms. After 30 days, the
pain was totally relieved in in 38 percent of those taking Flavay™,
the swelling disappeared in 26 percent (the circumference of the
legs was measured above the ankle), and 11 percent experienced a
decrease in the feeling of heaviness in their lower limbs. After
60 days, the pain was totally relieved in 67 percent of those
taking Flavay™, the swelling disappeared in 63 percent, and the
decrease in heaviness jumped to 33 percent.
Recovery
from Sports Injuries and Postoperative Inflammation
Soccer
players in Australia experienced significantly less
swelling than those who did not take Flavay™.
|
Research has shown that
Flavay’s™ ability to strengthen vascular walls may help the
body to repair injuries faster. In an Australian study conducted
on two groups of soccer players that had sustained injuries, those
that consumed Flavay™ for ten days following their injuries
experienced significantly less swelling than those who did not
and, in some of those taking Flavay™, the swelling had
completely disappeared. Other research has demonstrated the ways
in which Flavay™ may actually inhibit inflammation including
double-blind studies conducted in France which showed that Flavay™
can reduce postoperative inflammation.
Nitric
Oxide Toxicity and Chronic Inflammation
Contemporary
research shows that elevated levels of nitric oxide
appear to contribute to arthritis and other disorders
associated to abnormal immune or inflammatory responses.
|
Contemporary research shows that
elevated levels of nitric oxide (sometimes referred to as
"NO") appear to contribute to a number of seemingly
different disorders that all have a common element of abnormal
immune or inflammatory responses.
Studies of arthritis, colitis,
and other inflammatory disorders have all demonstrated elevated
levels of nitric oxide synthesis. In the case of arthritis, nitric
oxide has been implicated in the destruction of the pericellular
and extracellular matrix of cartilage in arthritis.
Arthritis is an umbrella term for
more than 100 different conditions that produce either
inflammation of connective tissue (joints and tendons) or
degeneration of the articular cartilage, a wearing down of the
protective covering that cushions the ends of bones, allowing
bones to rub together without causing damage to the joints.
When joints become arthritic,
they become inflamed and enlarged, interfering with the normal
flow of blood. For example, when you bend an arthritic knee, you
cut off blood flow to the area which sets into motion of a chain
of events that will lead to a burst of free radicals when the
blood flow returns (known as "reperfusion injury"). When
you release the knee, a proliferation of free radicals causes the
area to become even more inflamed, contributing to the
degeneration of the joint, which becomes more swollen and worn
down.
High levels of nitric oxide have
also been implicated in the inflammation that is associated with
asthma. Asthmatics exhale significantly higher levels of nitric
oxide and type II nitric oxide synthase (also known as "NOS")
expression is increased in biopsy specimens from asthmatics.
It's long been recognized that
nitric oxide is essential for normal blood circulation as it
controls the muscular tone of blood vessels and regulates
circulation and blood flow. However, excessive amounts of nitric
oxide can be deadly to the cardiovascular system and actually contribute
to disease and inflammation. High levels of nitric oxide can
restrict blood flow and promote production of more free radicals,
including the dangerous peroxynitrate.
Flavay™
can help regulate a healthy balance of nitric oxide
in the body.
|
Flavay™ can significantly
scavenge nitric oxide radicals. However, as we'll discuss next,
your body needs a certain amount of nitric oxide in order to
maintain good health. Nitric oxide is paradoxical. It can both
mediate normal physiological functions and it can be highly toxic.
Nitric oxide can act as an anti-inflammatory under normal health
conditions, but it can have the opposite effect and cause more
inflammation to an already inflamed area when overproduced. The
key, therefore, is to maintain the optimum balance of
this double-edged sword, nitric oxide.
Flavay™
and the Nitric Oxide Connection
Nitric oxide is a colorless gas
produced by many different cells in the body that, depending on
the situation, can be very good or very bad.
Nitric oxide plays several important roles in the body:
- Nitric oxide is an important
signaling molecule that turns genes on and off.
- By controlling the muscular
tone of blood vessels, nitric oxide regulates the
circulation and normalizes blood flow.
- Nitric oxide modulates
communication between brain cells and is instrumental in
helping us concentrate and learn new information, and also
in maintaining memory.
- When produced by immune
cells, nitric oxide fights infection, kills tumor cells and
promotes wound healing.
- Nitric oxide is essential
for perceiving pleasure and pain, and it helps translate
sexual excitement into penile erections.
- Nitric oxide aids in
digestion of food by helping to control gastric movements.
But nitric oxide can be very
destructive under other circumstances:
- Nitric oxide restricts blood
flow.
- When produced in excess by
immune cells, nitric oxide can trigger chronic inflammation,
which can cause arthritis, colitis, inflammatory bowel
disease and possibly cancer.
- Nitric oxide promotes
production of more free radicals.
- In the brain, nitric oxide
can hamper mental function and cause memory loss and brain
aging.
The real trouble starts when
nitric oxide encounters the superoxide free radical and becomes
peroxynitrate, which destroys antioxidants like glutathione,
vitamin E and common flavonoids, and damages proteins in the body.
As long as nitric oxide is produced in the right amount, it
remains friendly. But if nitric oxide is overproduced, the effect
can be very toxic. Research demonstrates that Flavay™ can help
to maintain the optimal level of nitric oxide by helping the body
to produce adequate levels—and to neutralize this free radical
where it does harm.
Superior
Antioxidant Support
Flavay™ is superior to other
antioxidants because its protective effects are multiplied in the
body. While it provides its own, powerful antioxidant protection,
it also supports the dynamic interplay between other antioxidants
in the body. Flavay's ability to “recycle,” or regenerate
vitamins C and E after they have quenched free radicals vastly
extends their unique antioxidant powers, helping to maintain an
optimal, synergistic antioxidant balance in the body.
Flavay™ is rapidly absorbed and
very quickly distributed throughout the body. As a free radical
fighter, Flavay™ comes to the aid of the body more quickly than
other antioxidants, reducing the potential for free radical damage
and the ravages of aging. Flavay™ also possesses more reactive
sites for neutralizing free radicals than other known
antioxidants. Furthermore, Flavay™ permits reactivity with both
positively and negatively charged free radical species. What this
means is that Flavay™ can “quench” or “scavenge”
(neutralize) a broad variety of free radicals. Highly reactive as
an antioxidant in both lipid (fat) and aqueous (water) phases,
Flavay™ neutralizes oxygen free radicals and is a valuable
protector of healthy cells in a variety of internal conditions.
This is a unique property among antioxidants, as most work either
in lipid or aqueous phases, but not both. As a free radical
scavenger, Flavay™
is like an antioxidant prize fighter that can successfully take on
all challengers, big or small, in any kind of weather.
"Radical
Scavenger Effect" of Flavay™
Protected by U.S. Patent No. 4,698,360
Flavay's™ strong antioxidant
power is patented—as a scavenger of the free radicals
that play a major role in the initiation, duration and breakdown
of inflammation and the degradation of collagen.
|
"[A]
method for preventing and fighting the harmful
biological effects of free radicals in the
organism of warm blooded animals and more especially human
beings, namely cerebral involution, hypoxia
following atherosclerosis, cardiac or cerebral infarction,
tumour promotion, inflammation, ischaemia,
alterations of the synovial liquid, collagen
degradation, among others. The method consists in
administering to said animals and especially to human
beings an amount, efficient against said effects, of a
plant extract with a proanthocyanidins content which has a
radical scavenger effect"—Dr. Jack
Masquelier, U.S. Patent No. 4,698,360.
|
Flavay™ is
the product—used in the actual experiments—by
which Dr. Jack Masquelier established and patented the "Radical
Scavenger Effect."
|
This means that your immune system works better so that your
joints hurt less and your blood flows better—all because of
Flavay™.
CLICK HERE TO SEE WHAT THE CUSTOMERS ARE SAYING
|
|
All About Flavay
| Flavay Plus | What Does
it Do? | Proven Safety
| Directions for Use
Q&A | Comparative Analysis | Endorsements & Testimonials
| How to Purchase
HealthyBodynMind
1-877-352-8042 • (306) 352-8042 • info@healthybodynmind.com
Protected by U.S. PATENT NO. 4,698,360 and international
patents.
Copyright © 1995-2004 Healthy Publisher.
All rights reserved. Healthy Source LLC
|
Statements made herein have not been
evaluated by the Food and Drug Administration. These products are
not intended
to diagnose, treat, cure or prevent any disease.
|
REFERENCES:
Top  |
Masquelier, J. Plant extract with
a proanthocyanidins content as a therapeutic agent having radical scavenging
effect and use thereof. U.S. Patent No. 4,698,360, 1987.
Masquelier, J. A lifetime devoted to OPC and
Pycnogenols. Alfa Omega
Editrice,
Pub., 1996.
Schwitters, B.,
Masquelier, J. OPC in practice. Alfa Omega
Editrice, Publishers,
1995.
Kilham, C., Masquelier, J.
OPC: The miracle antioxidant. Keats Publishing,
Inc., 1997.
Packer, L., et al. The antioxidant miracle: your complete plan. John Wiley
& Sons, Inc., 1999.
Packer, L., et al. Antioxidant food supplements in human health. Academic
Press, 1999.
Lincoln, J., Hoyle, C.H.V., Burnstock, G., Nitric oxide in health and disease.
Cambridge University Press, 1997.
Moncada, S., Nistico, G.,
Bagetta, G., Higgs,
E.A. Nitric oxide and the
cell. Princeton University Press, 1998.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme activities
of procyanidines from vitis vinifera. A mechanism for their capillary protective
action. Arzneimittelforschung, 44: 592-601, 1994.
Passwater, R.A. The antioxidants: the nutrients that guard your body. Keats
Publishing, Inc., 1985.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants.
Keats Publishing, Inc., 1995.
Facino RM, et al. Free radical scavenging action and anti-enzyme activities
of procyanidines from Vitis vinifera. A mechanism for their capillary protective
action. Arzneimittelforschung, 44: 592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant to the
action of mammalian collagenase. Experientia, 37: 221-223, 1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres
procyanidoliques.
Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains
flavonoides.
A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques
totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres
flavonoliques.
Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action des
oligomeres procyanidoliques sur des cellules mesenchymateuses en culture.
Ii l’attachment des fibres elastiques aux cellules. (Study of the effect
of procyanidolic oligomers on mesenchymal cells in culture. Ii attachment
of elastic fibers to the cells.) Pat Biol, (30)6:601-7, 1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular and crystal
structure of (+)-2,3-trans-3,4-trans-leucocyanidin [(2r,3s,+r)-(+)-3,3’,
4.4’, 5.7’-Hexahydroxyflavan] dihydrate, and comparison of its
heterocyclic ring conformation in solution and the solid state. Journal
of the Chemical Society; Perkin Transactions I 1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux
libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free radicals.
Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins b-1 and
b-3 from azuki beans to peroxyl radicals. Agric Biol Chem, 54(10) 1990.
pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different procyanidins
from grape seeds. Presented at a symposium, “Free radicals in biotechnology
and medicine.” Royal Society Of Chemistry, London January 1990, pp.
79-80.
Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase
durch flavonoide und phenolderivate im vergleich nit deren 02 radikalfangereigenschaften”
Arch Pharm, (Weinheim) 313 (1980) pp. 330-337.
Lombard, J., et al. The brain wellness plan. Kensington Pub. Corp., 1998.
Flesch M., et al., Effects of red and white wine on endothelium-dependent
vasorelaxation of rat aorta and human coronary arteries. Am J Physiol 1998;275:1183-94.
Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM. Isolation
and characterization of endothelium-dependent vasorelaxing compounds from
grape seeds. J Agr & Food Chem In press.
Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation, endothelium,
and wine. BioFactors 1997;6:455-459.
Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey RG. Endothelium-dependent
vasorelaxation caused by various plant extracts. J Cardiovasc Pharmacol
1995;26:90-95.
Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent vasorelaxing
activity of wine and other grape products. Amer J Physiol 1993;265:H774-H778.
Kuttan, R., Donnelly,
P.V., Di Ferrante, N. Collagen treated with catechin
becomes resistant to the action of mammalian collagenase. Experientia, 37:
221-223, 1981.
Masquelier, J. Procyanidolic
oligomers. J Parums Cosm
Arom, 95: 89-97, 1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies that binding
of pycnogenols to elastin affects its rate of degradation by elastases.
Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem.
Pharm. Bull. 33:5079, 1985.
Harmand, M.F.,
Blanquet, P. The fate of total flavanolic oligomers extracted
from ‘vitus vinifera l.’ in the rat. European Journal of Drug
Metabolism and Pharmaccokinetics. 1978, No. 1 pp. 15-30.
Delrieu, P., Ding J.,
Escande, B., Samain, D. Free-radical scavenging activity
of proanthocyanidolic oligomers encapsulated in glycospheres: an in vivo
and in vitro study. Cosmetology Department & S Biovectors, Ramonville
St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i converting
enzyme by flavanolic compounds: in vitro and in vivo studies. Planta
Medica,
May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-activite aniagoniste vis-a-vis des mediateurs de l’inflamation.
Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G.,
Hugonot, H. Evolution de la resistance
capillaire,
spontanement ou artificiellement diminuee par l’action d’une substance
capillaro-toxique chez des personnes agees--action benefique d’un agnet
actif sur la micro-circulation: l’Endotelon. Inform. Therapeut. 1980.
pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude d’un
microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7, 1990.
Lagrue, G., Olivier-Martin, F.,
Grillot, A. “Etude des effets des oligomeres
du procyanidol sur las resistance capillaire dand l’hypertension arterielle
et certaines nephropathies.” Sen. Hosp. Paris 18-25 Septembre, 1981.
Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur
peripherique,
l’Endotelon. Actualite Therapeutique Gaz. Med. de France (87)22:2919-24,
1980.
Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice
de fragilite capillaire dan une population specifique: les sujets
cirrhotiques. Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres inferieurs
par un microangioprotecteur l’Endotelon. Bordeaux Med, 11:685-8, 1981.
Delacroix, P. Etude en double aveugle de l’Endotelon dans l’insuffisance
veineuse chronique. Therapeutique, la Revue de Medicine, (27-28) Sept. 1981.
pp. 1793-1802.
Thebaut, J.F, Thebaut, P.,
Vin, F. Etude de l’Endotelon dand les manifestations
fonctionnelles de l’insuffisance veineuse peripherique-resultats d’une
etude en double aveugle portant sur 92 patients.” Gazette Medicale,
(92)1, 1985. pp. 96-100.
Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and arachidonate
metabolism in platelets by procyanidins. Prostagland Leukotri Essent Fatty
Acids, 38:181-8, 1989.
Masquelier, J.
Pycnogenols: recent advances in the therapeutical activity
of procyanidins. Supplement of Planta Medica, Journal of Medicinal Plant
Research and Journal of Natural Products, July 1980 pp. 243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury: implications
in atherosclerosis. Free Rad Path & Med, (4)1988 pp. 99-106.
Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.”
pp. 88-93.
Gazave, J.M. “Notions recentes sur les capillaires”
unpub. bulletin
from the Laboratoire De Physiologie Patholigie pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation and
atherothrombosis.
Office International Vigne et du Vin, Nutrition and Health Unit, Paris France;
Drugs under Experimental and Clinical Research (Switz.) 25/2-3 (125-131),
1999.
Blaszo, G. Gabor, M.
Oedema-inhibiting effect of
procyanidin. Acta Physiologica
Academiae Scientiarum Hungaricae, Tomus 56(2):235-240, 1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase.
Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en
gynecologie. Essai
Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P “Une Etude Exemplaire Pour Un
Phlebotrope: l’etude
EIVE.’ Unpub., pp. 77-83.
Pfister, A., Simon,
M.T., Gazave, J.M. Sites de fixation des oligomeres
procyanidoliques dans la paroi des capillaires sanguins du poumon decobaye.
Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di
Ferrante, N. “Collagen treated with (+)
-catechin becomes resistant to the action of mammalian
collagenase.”
Laboratory of Connective Tissue Research, Dept. of Biochem. Baylor Col.
of Med., Houston TX. 28, May, 1980.
Gendre, P., Laparra, J.,
Barraud, E. “Effect protecteur des oligomeres
procyanidoliques sur le lathyrisme experimental chez le rat.” Ann.
Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P.,
Siou, A. Light vision and chorioretinal circulation.
Study of the effect of procyanidolic oligomer (Endotelon). Jn. Fr.
Opthalmol,
(11)5:453-460, 1988.
Boissin, J.P., Corbe C.,
Siou, A. Chorioretinal circulation and dazzling:
use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol Fr, 88(2):173-4,
177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside oligomers
effects on retinal function in myopic subjects. Ann Ott Clin Ocul, 114:85-93,
1988.
Saracco, J.B., Estachy,
G.M. Etude d l’Endotelon en
opthalmologie.
Gaz Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies.
Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr.
Opthalmol, 11:453,
1988.
Verin, M.M., Vildy, A.,
Maurin, J.F., Retinopathies et
O.P.C. Bordeaux
Medicale,
(16)11. pp. 1467-74, 1978.
Soyeux, A. et al.
Endotelon. Diabetic retinopathy and
hemorheology. Bull
Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. “Les oligomeres procyanidoliques dans le traitement de
la fragilite capillaire et de la retinopathie chez les diabetiques. A propos
de 26 cas.” Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques:
Endotelon, dans la retinopathie diabetique (a propos de 30 observations).
Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results of a double-blind
study versus placebo in 32 female patients. Ann Chir Plast Esthet 29(4):393-5,
1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism in
rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62, 1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels.
Angiologica,
9:355-374, 1972.
Havsteen, B.
Flavonoids, a class of natural products of high pharmacological
potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer, H.J. Berkhauser
Verlag, Vol. 7/1, Univ. of
Marburg/Lahn, Ger., 1977.
Masquelier, J. Action protectrice du vin sur l’ulcere
gastrique. Resultats,
p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by flavonoids
and bioflavonoids. Planta Medica, 5116-20, 1985.
Shaw, R. How [Australian] PycnoGenol [MASQUELIER’s®] Helps Sports
People.
Masquelier, J. Procyanidolic oligomers
(leucocyanidins). Parfums Cosmet
Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques (Endotelon) dans le traitement des lymphoedemes
post-therepeutiques de members
superieurs. Symposium Satellite, Congres International d’Angiologie,
Toulouse, France, 4-7 Oct. 1989.
Fahey, T.D., Pearl M. Hormonal effects of phosphatidylserine during 2 weeks
of intense training. Abstract submitted to national meeting of the Amer
College of Sports Medicine, June 1998.
Monteleone, P., Maj, M.,
Beinat, L., Natale, M.,
Kemali, D. Blunting by
chronic phosphatidylserine administration of the stress-induced activation
of the hypothalamo-pituitary-adrenal axis in healthy men. Eur J Clin Pharm
43: 385–388, 1992.
Fahey, T.D., et al. The hormonal and perceptive effects of phosphatidylserine
administration during two weeks of resistive exercise-induced overtraining.
Bio of Sport 15(3):135-44, 1998.
Laparra, J., Michaud, J.
Masquelier, J. Action des oligomeres procyanidoliques
sur le cobaye carence en vitamin c. Tavaux Originaux, University of Bordeaux,
1976.
Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’oxydation
de l’acide ascorbique par les ions cuivriques. Bull. de la Societe
de Chimie Biologique XXXIII (3-4) 1951. pp. 302-304.
Masquelier, J. Action comparee de divers facteurs vitaminiques p sur l’acide
ascorbique-oxydase. Bull. de la Societe de Chimie Biologique XXXIII (3,4)
1951. pp.304-306
Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T.,
Nonaka, G., Mishioka,
I. “Inhibitory effects of tannins on hyaluronidase activation and on
the degranulation from rat mesentery mast cells.” Chem. Pharm. Bull.
33(11)1985. 5079-5082.
Reiman, H.J., Lorenz, M., Fischer, R.,
Frolich, H., Meyer, J. “Histamine
and acute haemorrhagic lesions in rat gastric mucosa: prevention of stress
ulcer formulation by (+)-catechin, an inhibitor of specific histidine decarboxylase
in vitro.” Dirkhauser Verlag,Vol. 7/1, 1977.
Pariente, J.J.
Parientl-Amsellem, J. “Les oedemes
post-traumatoqies
chez le sportif: essai controle de l’Endothelon.” Actualite Therapeutique
90(3) 2/11 1983 pp. 231-235.
Masquelier, J., et al. “Flavonoids et Pycnogenols” Int J Vit Nut
Res, (49)3:307-311, 1979.
Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem. Toxicol.
25(2):135-9, 1987.
Pantaleoni, G.C.,
Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica
Report, 1971.
Laparra, J., et al., Acta
Therapeutica, 4:233, 1978.
Volkner, Wolfgang Muller,
Ewald, Micronucleus assay in bone marrow cells
of the mouse with Pycnogenol. Cytotest Cell Research GmbH & Co., projects
143010 & 143021; Feb. 1989.
Acute and chronic toxicity tests. International Bio-Research, Inc., Hanover,
Germany, 1967-1971.
Dumon, M., Michaud, J.,
Masquelier, J. Proanthocyanidin content in vegetable
extracts to be used in the preparation of medicines. Bull. Soc. Pharm. Bordeaux,
129:51-65, 1990.
|
|
